Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alantos Pharmaceuticals

Division of Amgen Inc.
www.alantos.com

Latest From Alantos Pharmaceuticals

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.
BioPharmaceutical

Deals Shaping the Medical Industry (7/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Amgen's Biotech Shopping Spree

It was always a question of when, not if. Amgen needed to do something to provide for its post-EPO future; now the action has started. The big biotech went on a $720 million cash shopping spree in the early part of June, buying first Ilypsa Inc. for $420 million, then swallowing up Alantos Pharmaceuticals for $300 million a couple of days later.
BioPharmaceutical

European Financing: The Money's Back, But How Do You Get It?

Two of Europe's handful of IPOs this season are struggling to stay afloat. Bankruptcies continue among private German biotechs. Yet VCs have more money than ever and two of the European biotech flotations were the second- and third-largest globally during this window. What do Europe's biotechs need to do in this new, cautious and contradictory era in order to raise private funds and survive on the open markets? In Vivo Europe Rx asked three top leading European financiers.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Therascope AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Keith E Dionne, PhD, Pres. & CEO
    Neil Exter, CBO
    Arthur Tareras, PhD, VP, Drug Discovery
  • Contact Info
  • Alantos Pharmaceuticals
    Phone: (617) 577-0011
    840 Memorial Dr.
    2nd Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register